Industry / innovation partners

China’s PD-1/VEGF Bet Challenges the Lung Cancer Backbone

The ASCO Drug Race Still Runs Through Genomic Testing

High-Risk Prostate Cancer Moves Before the Metastatic Clock Starts

Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority

Lenacapavir Turns HIV Prevention Into an Access Stress Test

WHO’s New AMR Plan Makes Stewardship and Access a Single Test

Can cortisol become the next target in type 2 diabetes?

An ADC Steps Into the First-Line Gap in Triple-Negative Breast Cancer

Alpha Radioligand Therapy Moves Prostate Cancer Into a New Infrastructure Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
